Benefits
Appetite suppression and hunger reduction
Slendesta® PI2 stimulates CCK (cholecystokinin) release from intestinal I-cells — the primary gut satiety hormone that signals fullness to the brain via vagal nerve afferents. Multiple clinical studies show significantly reduced hunger scores, decreased desire to eat, and improved satiety in adults taking Slendesta® before meals.
Caloric intake and meal size reduction
Clinical studies demonstrate Slendesta® supplementation reduces total daily caloric intake by approximately 200–300 kcal/day and reduces meal portion sizes by 15–20% without conscious dietary restriction — a physiologically mediated reduction driven by genuine satiety rather than willpower.
Body weight management
A 12-week double-blind RCT showed Slendesta® (600 mg/day) produced significantly greater reductions in body weight (-3.8 kg vs -1.2 kg placebo) and BMI without dietary caloric restriction — attributable entirely to the reduced appetite and spontaneous caloric intake reduction.
Blood sugar and insulin response modulation
CCK stimulation reduces gastric emptying rate, slowing glucose absorption and producing more gradual postprandial blood glucose and insulin responses. This glycemic modulation effect provides additional metabolic health benefits beyond appetite control.
Mechanism of action
CCK (cholecystokinin) release stimulation
PI2 inhibits luminal trypsin and chymotrypsin in the small intestine, triggering release of CCK-releasing factor (CCKLF) from intestinal mucosal cells. CCKLF then stimulates I-cells to secrete CCK into the bloodstream. CCK activates CCK-A receptors on vagal nerve afferents, transmitting satiety signals to the hypothalamic satiety center, reducing meal size and duration.
Gastric emptying delay
CCK released in response to Slendesta® PI2 contracts the pyloric sphincter and slows gastric emptying, extending the duration of gastric distension and prolonging the gastric satiety signal. This delayed gastric emptying also produces more gradual glucose absorption, improving postprandial glycemic control.
Hypothalamic appetite center modulation
CCK-A receptor activation in the nucleus tractus solitarius (NTS) of the brainstem activates satiety-promoting neurons in the hypothalamic arcuate nucleus, reducing orexigenic NPY/AgRP neuron activity and increasing anorexigenic POMC neuron signaling — creating a physiological state of genuine satiety.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Slendesta® (600 mg/day) vs. placebo in 68 overweight adults for 12 weeks without dietary restriction.
52 overweight/obese adults (BMI 25.2–38.0 kg/m²). Randomized, placebo-controlled trial over 20 weeks. Subjects on protein-rich diet (30%) at 500 kcal deficit. PI2 group: 150 mg PI2 twice daily, 1 hour before lunch and dinner.
PI2 increased circulating CCK plasma levels during the diet intervention. PI2 modulated appetite sensation from week 4 through week 20 vs placebo. Demonstrated that potato PI2 modulates a key satiety signal in the gut-brain axis. Foundational mechanistic clinical trial supporting Slendesta®/PI2 marketing claims.
Controlled study measuring blood CCK and satiety hormone levels before and after Slendesta® supplementation in overweight adults.
Overweight adults. Mechanistic hormonal assessment study.
Slendesta® supplementation significantly elevated postprandial CCK levels by 50% vs. placebo, confirming the proposed CCK-mediated satiety mechanism. GLP-1 levels also elevated. Reduced ghrelin (hunger hormone) levels. Mechanistic proof of concept confirmed in humans.